Business Description
NervGen Pharma Corp
NAICS : 325412
SIC : 3741
Share Class Description:
STU:9UA: Ordinary SharesCompare
Compare
Traded in other countries / regions
NGEN.CanadaNGENF.USA9UA.Germany IPO Date
2024-06-27Description
NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 174.74 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -2.6 | |||||
| 3-Year EPS without NRI Growth Rate | 5.8 | |||||
| 3-Year FCF Growth Rate | 0.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.38 | |||||
| 9-Day RSI | 50.54 | |||||
| 14-Day RSI | 48.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.78 | |||||
| Quick Ratio | 1.78 | |||||
| Cash Ratio | 1.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.2 | |||||
| Shareholder Yield % | -12.96 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -274.97 | |||||
| ROA % | -108.18 | |||||
| ROIC % | -187.75 | |||||
| 3-Year ROIIC % | -54.54 | |||||
| ROC (Joel Greenblatt) % | -14064.19 | |||||
| ROCE % | -280.97 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 14.16 | |||||
| Price-to-Tangible-Book | 15.91 | |||||
| EV-to-EBIT | -6.86 | |||||
| EV-to-EBITDA | -6.89 | |||||
| EV-to-FCF | -12.6 | |||||
| Price-to-Net-Current-Asset-Value | 15.91 | |||||
| Price-to-Net-Cash | 17.5 | |||||
| Earnings Yield (Greenblatt) % | -14.6 | |||||
| FCF Yield % | -6.3 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NervGen Pharma Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.253 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 48.42 | ||
| 14-Day ATR (€) | 0.06931 | ||
| 20-Day SMA (€) | 1.7525 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 1.61 - 2.16 | ||
| Shares Outstanding (Mil) | 70.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NervGen Pharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NervGen Pharma Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
NervGen Pharma Corp Frequently Asked Questions
What is NervGen Pharma Corp(STU:9UA)'s stock price today?
The current price of STU:9UA is €1.75. The 52 week high of STU:9UA is €2.16 and 52 week low is €1.61.
When is next earnings date of NervGen Pharma Corp(STU:9UA)?
The next earnings date of NervGen Pharma Corp(STU:9UA) is .
Does NervGen Pharma Corp(STU:9UA) pay dividends? If so, how much?
NervGen Pharma Corp(STU:9UA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers